Note that some links may require subscriptions.
The FDA warned against “unscrupulous actors” touting unproven young blood infusions as cures for various ailments like Parkinson’s and Alzheimer’s …
… and shortly thereafter, Florida-based startup Ambrosia Health announced it had ceased treating patients with its plasma infusions that purported to reverse aging. (CBS News)
Trump’s plan to end HIV/AIDS might struggle to meet its goal in rural states. (NPR)
Health data experts say Facebook misleads its users into revealing personal health information. (The Hill)
The Supreme Court refused to hear an appeal to revive Maryland’s drug price-gouging law, affirming a lower-court ruling that the law violated a Constitutional prohibition on state regulation of interstate commerce. (Reuters)
Nearly 9,000 individuals in Arkansas lost Medicaid coverage over the state’s new work requirement. (MPR News)
Nut consumption was tied to lower cardiovascular disease incidence in a study of individuals with type 2 diabetes. (Medical Xpress)
Long-used bladder cancer drug bacillus Calmette-Guérin, or BCG, is in short supply. (STAT News)
Should sexual dysfunction therapies be covered by health insurers? (Kaiser Health News)
Merck’s pembrolizumab (Keytruda) gets FDA approval for adjuvant therapy in resected, locally advanced melanoma, while in late-stage liver cancer, a phase III trial of pembrolizumab failed to meet its primary survival endpoints.
In other approval news, the long-acting factor VIII replacement therapy turoctocog alfa pegol (Esperoct) gets an OK from the agency for adults and kids with hemophilia A, Novo Nordisk announced.
And just one more: Xellia Pharmaceuticals announced FDA approval of its proprietary vancomycin formulation, which remains stable and “ready to use” at room temperature for up to 16 months.
Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]